Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.
Michael BD, Dunai C, Needham EJ, Tharmaratnam K, Williams R, Huang Y, Boardman SA, Clark JJ, Sharma P, Subramaniam K, Wood GK, Collie C, Digby R, Ren A, Norton E, Leibowitz M, Ebrahimi S, Fower A, Fox H, Tato E, Ellul MA, Sunderland G, Held M, Hetherington C, Egbe FN, Palmos A, Stirrups K, Grundmann A, Chiollaz AC, Sanchez JC, Stewart JP, Griffiths M, Solomon T, Breen G, Coles AJ, Kingston N, Bradley JR, Chinnery PF, Cavanagh J, Irani SR, Vincent A, Baillie JK, Openshaw PJ, Semple MG; ISARIC4C Investigators; COVID-CNS Consortium; Taams LS, Menon DK. Michael BD, et al. Among authors: coles aj. Nat Commun. 2024 Apr 4;15(1):2918. doi: 10.1038/s41467-024-47320-6. Nat Commun. 2024. PMID: 38575615 Free PMC article. No abstract available.
Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.
Michael BD, Dunai C, Needham EJ, Tharmaratnam K, Williams R, Huang Y, Boardman SA, Clark JJ, Sharma P, Subramaniam K, Wood GK, Collie C, Digby R, Ren A, Norton E, Leibowitz M, Ebrahimi S, Fower A, Fox H, Tato E, Ellul MA, Sunderland G, Held M, Hetherington C, Egbe FN, Palmos A, Stirrups K, Grundmann A, Chiollaz AC, Sanchez JC, Stewart JP, Griffiths M, Solomon T, Breen G, Coles AJ, Kingston N, Bradley JR, Chinnery PF, Cavanagh J, Irani SR, Vincent A, Baillie JK, Openshaw PJ, Semple MG; ISARIC4C Investigators; COVID-CNS Consortium; Taams LS, Menon DK. Michael BD, et al. Among authors: coles aj. Nat Commun. 2023 Dec 22;14(1):8487. doi: 10.1038/s41467-023-42320-4. Nat Commun. 2023. PMID: 38135686 Free PMC article.
Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses.
Needham EJ, Ren AL, Digby RJ, Norton EJ, Ebrahimi S, Outtrim JG, Chatfield DA, Manktelow AE, Leibowitz MM, Newcombe VFJ, Doffinger R, Barcenas-Morales G, Fonseca C, Taussig MJ, Burnstein RM, Samanta RJ, Dunai C, Sithole N, Ashton NJ, Zetterberg H, Gisslén M, Edén A, Marklund E, Openshaw PJM, Dunning J, Griffiths MJ, Cavanagh J, Breen G, Irani SR, Elmer A, Kingston N, Summers C, Bradley JR, Taams LS, Michael BD, Bullmore ET, Smith KGC, Lyons PA, Coles AJ, Menon DK; Cambridge NeuroCOVID Group; CITIID-NIHR COVID-19 BioResource Collaboration; Cambridge NIHR Clinical Research Facility. Needham EJ, et al. Among authors: coles aj. Brain. 2022 Nov 21;145(11):4097-4107. doi: 10.1093/brain/awac321. Brain. 2022. PMID: 36065116 Free PMC article.
Addressing ethnic disparities in neurological research in the United Kingdom: An example from the prospective multicentre COVID-19 Clinical Neuroscience Study.
van Wamelen DJ, Rota S, Hartmann M, Martin NH, Alam AM, Thomas RH, Dodd KC, Jenkins T, Smith CJ, Zandi MS, Easton A, Carr G, Benjamin LA, Lilleker JB, Saucer D, Coles AJ, Wood N, Ray Chaudhuri K, Breen G, Michael BD; COVID-CNS consortium. van Wamelen DJ, et al. Among authors: coles aj. Clin Med (Lond). 2024 May;24(3):100209. doi: 10.1016/j.clinme.2024.100209. Epub 2024 Apr 19. Clin Med (Lond). 2024. PMID: 38642613 Free PMC article.
Visual outcome measures in clinical trials of remyelinating drugs.
Riboni-Verri G, Chen BS, McMurran CE, Halliwell GJ, Brown JWL, Coles AJ, Cunniffe NG. Riboni-Verri G, et al. Among authors: coles aj. BMJ Neurol Open. 2024 Feb 19;6(1):e000560. doi: 10.1136/bmjno-2023-000560. eCollection 2024. BMJ Neurol Open. 2024. PMID: 38389586 Free PMC article. Review.
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G, Petrie J, Duffy KEM, Glover R, Hullock K, Papaioannou D, Roldan E, Beecher C, Bursnall M, Ciccarelli O, Coles AJ, Cooper C, Giovannoni G, Gabriel I, Kazmi M, Kyriakou C, Nicholas R, Paling D, Peniket A, Scolding N, Silber E, de Silva T, Venneri A, Walters SJ, Young C, Muraro PA, Sharrack B, Snowden JA; StarMS trial team. Brittain G, et al. Among authors: coles aj. BMJ Open. 2024 Feb 5;14(2):e083582. doi: 10.1136/bmjopen-2023-083582. BMJ Open. 2024. PMID: 38316583 Free PMC article.
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G, Freedman MS, Ziemssen T, Shiota D, Rawlings AM, Wong AT, Chirieac M, Montalban X. Coles AJ, et al. Ther Adv Neurol Disord. 2023 Sep 21;16:17562864231194823. doi: 10.1177/17562864231194823. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37745914 Free PMC article.
89 results